J C Torre Alonso - JoVE Visualize

Showing results (1-10 of 14) with videos related to

Pageof 2

Sort By:

Annals of the Rheumatic Diseases|December 21, 2006

Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexateJ Gratacós, E Casado, J Real, et al.

Annals of the Rheumatic Diseases|May 1, 1990

HLA antigens in psoriatic arthritis subtypes of a Spanish populationC López-Larrea, J C Torre Alonso, A Rodriguez Perez, et al.

Annals of the Rheumatic Diseases|December 14, 2002

A polyarticular onset predicts erosive and deforming disease in psoriatic arthritisR Queiro-Silva, J C Torre-Alonso, T Tinturé-Eguren, et al.

Scandinavian Journal of Rheumatology|October 30, 2004

The effect of HLA-DR antigens on the susceptibility to, and clinical expression of psoriatic arthritisR Queiro-Silva, J C Torre-Alonso, T Tinturé-Eguren, et al.

British Journal of Rheumatology|July 1, 1994

Decrease in detectable complement receptor type 1 levels on erythrocytes from patients with psoriatic polyarthritisD Rivas, J L Riestra-Noriega, J C Torre-Alonso, et al.

Journal of Autoimmunity|August 1, 1995

Upregulated expression of IL-4 receptors and increased levels of IL-4 in rheumatoid arthritis patientsD Rivas, L Mozo, J Zamorano, et al.

Annals of the Rheumatic Diseases|December 1, 1996

Annexin V autoantibodies in rheumatoid arthritisM I Rodríguez-García, J A Fernández, A Rodríguez, et al.

British Journal of Rheumatology|August 1, 1991

Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patientsJ C Torre Alonso, A Rodriguez Perez, J M Arribas Castrillo, et al.

Rheumatology (Oxford, England)|August 25, 2005

Effectiveness of reducing infliximab dose interval in non-responder patients with refractory spondyloarthropathies. An open extension of a multicentre studyE Collantes-Estevez, M C Muñoz-Villanueva, P Zarco, et al.

The Journal of Rheumatology|June 21, 2001

TNF-238A promoter polymorphism contributes to susceptibility to ankylosing spondylitis in HLA-B27 negative patientsS González, J C Torre-Alonso, J Martínez-Borra, et al.

Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:

Pageof 2

Annals of the Rheumatic Diseases|December 21, 2006

Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexateJ Gratacós, E Casado, J Real, et al.

Annals of the Rheumatic Diseases|May 1, 1990

HLA antigens in psoriatic arthritis subtypes of a Spanish populationC López-Larrea, J C Torre Alonso, A Rodriguez Perez, et al.

Annals of the Rheumatic Diseases|December 14, 2002

A polyarticular onset predicts erosive and deforming disease in psoriatic arthritisR Queiro-Silva, J C Torre-Alonso, T Tinturé-Eguren, et al.

Scandinavian Journal of Rheumatology|October 30, 2004

The effect of HLA-DR antigens on the susceptibility to, and clinical expression of psoriatic arthritisR Queiro-Silva, J C Torre-Alonso, T Tinturé-Eguren, et al.

British Journal of Rheumatology|July 1, 1994

Decrease in detectable complement receptor type 1 levels on erythrocytes from patients with psoriatic polyarthritisD Rivas, J L Riestra-Noriega, J C Torre-Alonso, et al.

Journal of Autoimmunity|August 1, 1995

Upregulated expression of IL-4 receptors and increased levels of IL-4 in rheumatoid arthritis patientsD Rivas, L Mozo, J Zamorano, et al.

Annals of the Rheumatic Diseases|December 1, 1996

Annexin V autoantibodies in rheumatoid arthritisM I Rodríguez-García, J A Fernández, A Rodríguez, et al.

British Journal of Rheumatology|August 1, 1991

Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patientsJ C Torre Alonso, A Rodriguez Perez, J M Arribas Castrillo, et al.

Rheumatology (Oxford, England)|August 25, 2005

Effectiveness of reducing infliximab dose interval in non-responder patients with refractory spondyloarthropathies. An open extension of a multicentre studyE Collantes-Estevez, M C Muñoz-Villanueva, P Zarco, et al.

The Journal of Rheumatology|June 21, 2001

TNF-238A promoter polymorphism contributes to susceptibility to ankylosing spondylitis in HLA-B27 negative patientsS González, J C Torre-Alonso, J Martínez-Borra, et al.

Pageof 2